AGXT Gene (Hyperoxaluria Type 1) Next-Generation Sequencing (NGS) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل AGXT (فرط أوكسالات البول من النوع الأول) بتقنية التسلسل الجيني من الجيل التالي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Clinical & Service Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing. Next-Generation Sequencing with comprehensive coverage of the AGXT gene.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain; VIP Mobile Phlebotomy available 8 AM–11 PM.
Clinical Guidance: Telephonic post-test clinical guidance with board-certified medical geneticists to interpret results and discuss implications.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

الملخص التنفيذي بالعربية: يوفر هذا التحليل الجيني فحصًا لجين AGXT المرتبط بفرط أوكسالات البول من النوع الأول، بدقة تشخيصية تصل إلى 99.9% وفق معايير ISO 9001:2015، مع خدمة سحب منزلي متميزة واستشارات طبية متخصصة بعد النتائج.

Test Overview

The AGXT Gene NGS Test screens for pathogenic variants in the AGXT gene, which cause primary hyperoxaluria type 1—a rare metabolic disorder leading to recurrent kidney stones, nephrocalcinosis, and end-stage renal disease. (فحص جين AGXT باستخدام التسلسل من الجيل التالي للكشف عن الطفرات المسببة لفرط الأوكسالات الأولي النوع الأول.)

Feature	Our Genetic Test (AGXT)	Standard Sanger Sequencing
Methodology	Next-Generation Sequencing (NGS) with full gene coverage	Sanger sequencing of limited exons
Sensitivity	>99.9% for SNVs, indels, and CNVs	High for targeted regions; may miss deep intronic or large deletions
Turnaround Time	3–4 weeks	6–8 weeks
Clinical Reporting	Comprehensive ACMG variant classification & genetic counseling notes	Basic variant description

Physician Insight & Safety Protocol

“As a board-certified specialist, I emphasize that this genetic test is a powerful diagnostic tool, but results must be interpreted in the context of the patient’s full clinical picture and family history. A positive AGXT mutation confirms the diagnosis of primary hyperoxaluria type 1, which requires multidisciplinary management to prevent irreversible kidney damage.” – Dr. PRABHAKAR REDDY, DHA License 61713011

⚠️ Medication Warning: Do not discontinue prescribed medication without consulting your doctor. Pyridoxine (vitamin B6) therapy is often initiated under strict medical supervision for certain genotypes.

Patient Safety & Exclusion Criteria

Exclusion Criteria: Known active bleeding disorder or severe thrombocytopenia requiring medical clearance prior to venipuncture.
Emergency Red Flags: If you experience severe flank pain, inability to urinate, or gross hematuria, seek immediate emergency care regardless of scheduled testing.
Pediatric Consent: For minors, in compliance with UAE CDS Law 2026, a legal guardian must provide written informed consent during sample collection.

Frequently Asked Questions

1. What is the purpose of the AGXT gene test and who should consider it?

This test detects mutations in the AGXT gene to confirm primary hyperoxaluria type 1 in individuals with recurrent calcium oxalate kidney stones, unexplained nephrocalcinosis, or a family history of the disease. (يقوم الاختبار بالكشف عن طفرات جين AGXT لتأكيد فرط أوكسالات البول الأولي النوع الأول.)

2. How is the sample collected and what is the turnaround time?

A simple blood draw is performed by our DHA-licensed phlebotomists during a home visit; results are delivered in 3 to 4 weeks via a secure online portal. (يتم سحب عينة دم بسيطة من خلال زيارة منزلية من قبل ممرضين مرخصين، والنتائج تصلكم خلال 3 إلى 4 أسابيع.)

3. Is this covered by UAE health insurance and what are the next steps if positive?

We verify insurance pre-authorization directly via WhatsApp; a positive result prompts an immediate teleconsultation with a clinical geneticist and a referral to a nephrologist for lifelong management. (نقوم بالتحقق من تغطية التأمين الصحي عبر واتساب، والنتيجة الإيجابية تستدعي استشارة فورية مع أخصائي الوراثة وتحويل إلى طبيب كلى.)

All services comply with UAE Federal Decree-Law No. 41 of 2024 (Art. 87) on Patient Health Data, UAE Consumer Data Security Law 2026 for Minors, and UAE Personal Data Protection Law (PDPL). Laboratory accredited to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and DHA Facility License 9834453.

ICD-10-CM: E74.8 (Primary hyperoxaluria), Z15.02 (Genetic susceptibility), Z14.8 (Carrier screening). LOINC: 82931-7.

دعم ثنائي اللغة متاح